Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Users of Dermal Fillers (US)

Articles with lock require a subscription to GLG News | Request a free trial
Sunil DhawanFebruary 8, 2008
Botox competitors to make market interesting
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Botox is  highly effective cosmetic product, albeit not long lasting. Patient satisfaction is high, and the cost is still not prohibitive. However the predictable and not always justified increases in price have forced many physicians to eagerly await the newer agents. The include products from...
Sunil DhawanFebruary 8, 2008
Enbrel effective in pediatric psoriasis
Analysis of: New Study Reports Enbrel (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This study will expand the use of Enbrel in newer populations. this is important in that Humira just received approval for adults, and the market has become more competitive. This is good news for children with severe resistant psoriasis.
December 19, 2007
Ustekinumab-new drug that gets to the core of psoriasis
Analysis of: Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com
Author: GLG Expert Contributor
This is exciting news in that P40 is a protein central to the pathogenesis of psoriasis and now utilizing this basic science knowledge long term remission of psoriasis, and inflammatory arthritis has occurred.  The good news is out. However, this is the first use of IL12/23 in human disease now...
December 17, 2007
Reloxin Will Have a Huge Impact on Younger Women Entering Cosmetic Dermatology
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: GLG Expert Contributor
Drysport has equivalent safety and efficacy data abroad to currently available Botox. A less expensive price point is anticipated.
December 17, 2007
Lots of Pomp and Circumstance but Can Revance Deliver?
Analysis of: Medicis and Revance Announce Strategic Collaboration | www.pipelinereview.com
Author: GLG Expert Contributor
Injections of botulinum toxin type A were the number one non-surgical procedure in 2006, with over 3 million total procedures. Retail U.S. aesthetic market of approximately $300 million-$400 million.  "Revance's proprietary drug delivery technology."
December 17, 2007
Cost is key, but not enough!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.
Sunil DhawanDecember 17, 2007
Centecor Ustekinumab- an impressive product for psoriasis
Analysis of: Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
 The new Centecor psoriasis product, Ustekinumab, is impressive in its efficacy. The PASI 75 reduction is equal or surpasses Remicade, the current leader in efficacy in psoriasis. This product has the advantage of being a self administered injection at home, rather than a prolonged IV injection...
Sunil DhawanDecember 17, 2007
Medicis and Revance topical botox promising.
Analysis of: Medicis and Revance Announce Strategic Collaboration | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
 This topical Botox product is promising in that it would require no injection, and would be better accepted by patients. Medicis investment in the company is a wise adjunct to their Reloxin product, which was recently submitted to the FDA. Both these products would offer significant competition...
December 14, 2007
Cost is the most critical factor in patient's decision to use Botox and soon Reloxin
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: GLG Expert Contributor
Medicis is widely respected by dermatologists who will have confidence in Reloxin because Medicis is marketing the product.  Price of using these modalities will decrease and use will increase.  As patients are happier the word will spread and use will increase even further.
December 13, 2007
Reloxin Gives Allergan's Botox A Run for the Money!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects....

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next41 to 50 of 100

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T13:45:22.160